JP2022141811A5 - - Google Patents

Download PDF

Info

Publication number
JP2022141811A5
JP2022141811A5 JP2022114274A JP2022114274A JP2022141811A5 JP 2022141811 A5 JP2022141811 A5 JP 2022141811A5 JP 2022114274 A JP2022114274 A JP 2022114274A JP 2022114274 A JP2022114274 A JP 2022114274A JP 2022141811 A5 JP2022141811 A5 JP 2022141811A5
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
heteroaryl
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022114274A
Other languages
English (en)
Japanese (ja)
Other versions
JP7549627B2 (ja
JP2022141811A (ja
Filing date
Publication date
Priority claimed from GBGB1509338.8A external-priority patent/GB201509338D0/en
Application filed filed Critical
Publication of JP2022141811A publication Critical patent/JP2022141811A/ja
Publication of JP2022141811A5 publication Critical patent/JP2022141811A5/ja
Application granted granted Critical
Publication of JP7549627B2 publication Critical patent/JP7549627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022114274A 2015-05-29 2022-07-15 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 Active JP7549627B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1509338.8A GB201509338D0 (en) 2015-05-29 2015-05-29 Combination therapy
GB1509338.8 2015-05-29
GB1516442.9 2015-09-16
GBGB1516442.9A GB201516442D0 (en) 2015-05-29 2015-09-16 Combination therapy
JP2020038089A JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020038089A Division JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Publications (3)

Publication Number Publication Date
JP2022141811A JP2022141811A (ja) 2022-09-29
JP2022141811A5 true JP2022141811A5 (https=) 2023-04-10
JP7549627B2 JP7549627B2 (ja) 2024-09-11

Family

ID=53677482

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018513923A Active JP6795585B2 (ja) 2015-05-29 2016-05-27 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2020038089A Active JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2022114274A Active JP7549627B2 (ja) 2015-05-29 2022-07-15 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018513923A Active JP6795585B2 (ja) 2015-05-29 2016-05-27 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2020038089A Active JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Country Status (5)

Country Link
US (4) US20180153888A1 (https=)
EP (2) EP3804723A1 (https=)
JP (3) JP6795585B2 (https=)
GB (2) GB201509338D0 (https=)
WO (1) WO2016193680A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
EP3464360B1 (en) 2016-05-27 2025-11-12 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
US11576873B2 (en) 2017-03-31 2023-02-14 The Curators Of The University Of Missouri Compositions for the treatment of drug-resistant tumors and methods of use thereof
US20200197385A1 (en) * 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
AU2019292207B2 (en) * 2018-06-27 2022-06-30 Oscotec Inc. Pyridopyrimidinone derivatives for use as Axl inhibitors
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) * 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
WO2022269605A1 (en) 2021-06-24 2022-12-29 Yeda Research And Development Co. Ltd. Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
KR20240156104A (ko) * 2023-04-21 2024-10-29 아주대학교산학협력단 면역 관문 억제제 저항성 극복을 위한 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2226211A1 (de) 1972-05-30 1973-12-13 Basf Ag N-substituierte iminocumarinfarbstoffe
AU2905199A (en) * 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6149495A (en) 1999-03-15 2000-11-21 Austin; Joseph James Confetti and theatrical snow delivery device
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
US8574827B2 (en) 2002-10-29 2013-11-05 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
WO2008045976A2 (en) 2006-10-10 2008-04-17 Squicor Compositions and methods for treating and diagnosing cancers
JP2008130120A (ja) 2006-11-17 2008-06-05 Sharp Corp 光ピックアップ装置
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
EP2078010B1 (en) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710046C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
EP2102356A2 (en) 2007-01-09 2009-09-23 Brystol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
WO2008127707A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
EP2139869A2 (en) * 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2205592B1 (en) 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5769969B2 (ja) 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
AU2008321835B2 (en) 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
WO2009082488A2 (en) 2007-12-24 2009-07-02 Bergenbio As Methods for creating and identifying functional rna interference elements
PL2387395T3 (pl) * 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
CA2759836A1 (en) 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
EP2482849B1 (en) * 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
MX337040B (es) * 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
EP2968525A4 (en) * 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
BR112017011536A2 (pt) 2014-12-02 2018-02-27 Celgene Corp terapias de combinação
AU2015366213B2 (en) * 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy

Similar Documents

Publication Publication Date Title
JP2022141811A5 (https=)
JP2020105211A5 (https=)
US20210369748A1 (en) Combination therapy for cancer treatment
RU2011132118A (ru) Ингибиторы axl для применения в комбинированной терапии для предотвращения, устранения или лечения метастизирующего рака
AU2015243379B2 (en) Tubulysin derivatives
JP2018524403A5 (https=)
JP2012515225A5 (https=)
KR20230142753A (ko) Cbl-b 억제제로서의 락탐
JP2011500801A5 (https=)
FI3796912T3 (fi) Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön
RU2018129308A (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
US20240343706A1 (en) Piperidine-2,6-dione derivatives which bind to cereblon, and methods of use thereof
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
WO2017214462A4 (en) Anti-cd98 antibodies and antibody drug conjugates
JP2016539138A5 (https=)
JP2007515419A5 (https=)
AU2020258568A1 (en) CD73 inhibitors
SG11202110615TA (en) Heterocyclic compounds and uses thereof
WO2024042497A1 (en) Anti-sez6 antibody drug conjugates
JP2023531522A5 (https=)
AU2021314401A1 (en) Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos
RU2004128465A (ru) Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
AU2020348825B2 (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
RU2020120043A (ru) Новые пиперидинильные производные в качестве ингибиторов убиквитин-специфической протеазы 7